Apasomics develops advanced drug delivery systems for bone diseases using nanotechnology and biotechnology. The company utilizes Apasomes, hydroxyapatite nanospheres that mimic natural bone cell processes to target bone tissue effectively. This technology improves the efficacy of therapeutics like bisphosphonates while providing controlled, sustained drug release and reducing systemic side effects.
Funding
Funding not disclosed
Founders
Product
Problem
Treatments for bone diseases, such as osteoporosis, often involve bisphosphonates that target osteoclasts. However, poor blood flow to bone tissue hinders effective drug delivery, necessitating higher dosages and increasing the risk of systemic side effects.
Solution
Apasomics has developed Apasomes, a hydroxyapatite nanosphere drug delivery system designed to enhance the efficacy of bone disease treatments. This biomimetic technology replicates the natural bone remineralization process, enabling Apasomes to target bone tissue and facilitate controlled, sustained drug release. By improving drug penetration and retention within bone, Apasomics aims to optimize therapeutic outcomes for conditions like osteoporosis while mitigating off-target adverse events.
Target Audience
The primary target audience includes pharmaceutical companies and biotechnology firms specializing in bone disease therapeutics and regenerative medicine.
Features
- Hydroxyapatite nanospheres engineered for targeted delivery to bone tissue.
- Biomimetic design that mimics natural bone cell exosome formation for drug encapsulation.
- Controlled and sustained release kinetics for enhanced therapeutic agent bioavailability.
- Demonstrated biocompatibility and low immunogenicity.
- Potential for improved efficacy of bone-targeting therapeutics, such as bisphosphonates.
- Nanoparticle formulation designed for stability in physiological environments.